Talphera, Inc. (TLPH)
(Delayed Data from NSDQ)
$0.79 USD
-0.01 (-1.25%)
Updated Oct 11, 2024 04:00 PM ET
3-Hold of 5 3
F Value D Growth D Momentum F VGM
Brokerage Reports
0 items in cart
Talphera, Inc. [TLPH]
Reports for Purchase
Showing records 1 - 4 ( 4 total )
Company: Talphera, Inc.
Industry: Medical - Drugs
2Q Recap: NEPHRO CRRT Study to Begin Enrolling Patients Imminently
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Talphera, Inc.
Industry: Medical - Drugs
1Q Recap: Minor Delay in Niyad NEPHRO CRRT Study Initiation to 2Q24; Our Positive Outlook Unaffected; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Talphera, Inc.
Industry: Medical - Drugs
4Q Recap; Niyad PMA Filing on Target by Year-End 2024; Cash Runway Out to Niyad''s Potential Approval in 2Q25; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Talphera, Inc.
Industry: Medical - Drugs
Cash Runway Extended Through Niyad''s Potential FDA Approval; Increasing PT to $6 on Reduced Financial Risk; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
|